Paper39770490
Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.
Jovalekic A and 15 others. Pharmaceuticals (Basel), 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights. Papers, record 39770490. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39770490
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Experiences from Clinical Research and Routine Use of Florbetaben Amyloid PET-A Decade of Post-Authorization Insights.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References90
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39366841 | Alzheimer's disease biomarkers and the tyranny of treatment. | EBioMedicine | 2024 | https://conductscience.org/library/papers/39366841 | PubMed |
| 2 | 37966285 | Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37966285 | PubMed |
| 3 | 31564456 | Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. | Cell | 2019 | https://conductscience.org/library/papers/31564456 | PubMed |
| 4 | 25824567 | Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. | Alzheimers Dement | 2015 | https://conductscience.org/library/papers/25824567 | PubMed |
| 5 | 18191617 | Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. | Lancet Neurol | 2008 | https://conductscience.org/library/papers/18191617 | PubMed |
| 6 | 30938796 | Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. | JAMA | 2019 | https://conductscience.org/library/papers/30938796 | PubMed |
| 7 | 37357283 | Diagnostic Biomarkers of Amyloid and Tau Pathology in Alzheimer's Disease: An Overview of Tests for Clinical Practice in the United States and Europe. | J Prev Alzheimers Dis | 2023 | https://conductscience.org/library/papers/37357283 | PubMed |
| 8 | 29653606 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29653606 | PubMed |
| 9 | 31594684 | Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. | Alzheimers Dement | 2019 | https://conductscience.org/library/papers/31594684 | PubMed |
| 10 | 29186280 | FACEHBI: A Prospective Study of Risk Factors, Biomarkers and Cognition in a Cohort of Individuals with Subjective Cognitive Decline. Study Rationale and Research Protocols. | J Prev Alzheimers Dis | 2017 | https://conductscience.org/library/papers/29186280 | PubMed |
| 11 | 29282327 | Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. | Neurology | 2018 | https://conductscience.org/library/papers/29282327 | PubMed |
| 12 | 38512444 | Comparison of consistency in centiloid scale among different analytical methods in amyloid PET: the CapAIBL, VIZCalc, and Amyquant methods. | Ann Nucl Med | 2024 | https://conductscience.org/library/papers/38512444 | PubMed |
| 13 | 35618838 | Performance of plasma phosphorylated tau 181 and 217 in the community. | Nat Med | 2022 | https://conductscience.org/library/papers/35618838 | PubMed |
| 14 | 35389071 | Quantification of amyloid PET for future clinical use: a state-of-the-art review. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/35389071 | PubMed |
| 15 | 33184233 | Association of β-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. | Neurology | 2021 | https://conductscience.org/library/papers/33184233 | PubMed |
| 16 | 35235702 | Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/35235702 | PubMed |
| 17 | 25741488 | Beta-amyloid imaging with florbetaben. | Clin Transl Imaging | 2015 | https://conductscience.org/library/papers/25741488 | PubMed |
| 18 | 25443857 | The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. | Alzheimers Dement | 2015 | https://conductscience.org/library/papers/25443857 | PubMed |
| 19 | 29107051 | Added value of 18F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. | Alzheimers Dement | 2018 | https://conductscience.org/library/papers/29107051 | PubMed |
| 20 | 36419238 | A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/36419238 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42720909 | Amyloid-β PET Radioligands in Alzheimer's Disease: From Plaque Detection to Biomarker-Guided Patient Stratification and Therapeutic Monitoring. | Mol Diagn Ther | 2026 | https://conductscience.org/library/papers/42720909 | PubMed |
| 41803942 | In-vitro interaction studies between the amyloid PET tracer florbetaben and the amyloid-beta targeting antibodies lecanemab and donanemab on AD brain samples reveal no interferences. | Alzheimers Res Ther | 2026 | https://conductscience.org/library/papers/41803942 | PubMed |
| 41238774 | Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases. | Sci Rep | 2025 | https://conductscience.org/library/papers/41238774 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39770490
GET https://conductscience.org/api/papers/v1/39770490/references?page=2